Abstract
The present invention relates to compositions and methods for treating cancer, particularly to agents that inhibit the expression and/or activity of the protein second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low p I (SMAC/Diablo). The inhibiting agents include RNA interference molecules silencing the expression of SMAC/Diablo and peptides modulating its interactions within the cell nucleus and mitochondria. The methods and agents of the present invention are useful in treating cancers associated with overexpression of SMAC/Diablo.
| Original language | English |
|---|---|
| Patent number | WO2019021289 |
| IPC | C12N 15/ 113 A I |
| Priority date | 18/01/18 |
| State | Published - 31 Jan 2019 |
